Printed From BioPortfolio.com
Mayo Clinic, sphingotec Collaborate for Evaluation & Use of Biomarkers to Improve Diagnosis
13:20 EST 1 Dec 2017 | HIT Consultants
sphingotec GmbH , a biotechnology company that develops biomarkers for the detection and management of diseases, has recently signed an agreement with Mayo Clinic to collaborate on the evaluation and use of several biomarkers that may improve the diagnosis of certain disease states, including kidney disease, breast cancer, sepsis, and cardiovascular disease. As part of the agreement, Mayo Clinic ... Read More
Original Article: Mayo Clinic, sphingotec Collaborate for Evaluation & Use of Biomarkers to Improve Diagnosis
